Figure 6From: Immunological evaluation of the new stable ultrasound contrast agent LK565: a phase one clinical trial Activation marker expression after LK565 application CD25, CD71, CD69 and CD11b expression on different cell types after LK565 exposure relative to starting value (n = 15, error bars show standard error).Back to article page